Bankrupt 23andMe To Delist Stock After Regeneron Deal
By Tom Zanki · May 27, 2025, 7:52 PM EDT
Bankrupt genetic testing provider 23andMe Inc. said Tuesday it will delist its stock from the Nasdaq exchange, following Regeneron Pharmaceuticals Inc.'s agreement last week to buy the defunct company....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login